News about Global Pharma

Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate

IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.

Global Pharma | 02/01/2025 | By Aishwarya |  458

NRx Pharmaceuticals Advances NRX-100 NDA Submission to FDA for Suicidal Depression Treatment

NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for the treatment of suicidal bipolar depression.

Global Pharma | 01/01/2025 | By Abha |  625

CardioSight Appoints Niv Ad, M.D. as its New Chief Medical Officer

CardioSight, Inc., developer of a revolutionary intravascular visualization and interventional platform, announces the appointment of Niv Ad, M.D., as Chief Medical Officer.

Global Pharma | 01/01/2025 | By Manvi |  120

Innocan Pharma Raises CAD 635,444.60 via Private Placement

Innocan Pharma Corporation has successfully closed a non-brokered private placement, raising CAD 635,444.60. The proceeds are earmarked for advancing its proprietary CBD-loaded liposome technology and general corporate purposes.

Global Pharma | 01/01/2025 | By Manvi |  139

Brii Biosciences Acquires IP Rights for BRII-179 from VBI Vaccines for USD 18 Million

Brii Biosciences Ltd. has acquired the intellectual property and assets of BRII-179 from VBI Vaccines, Inc. and its creditors for USD 18 million, securing full ownership and uninterrupted clinical supply for advancing late-stage development of chronic Hepatitis B therapies.

Global Pharma | 01/01/2025 | By Manvi |  437

ADC Therapeutics Completes Phase 3 Enrollment in LOTIS-5 Trial

ADC Therapeutics SA has completed enrollment in the Phase 3 LOTIS-5 trial, evaluating ZYNLONTA (loncastuximab tesirine-lpyl) with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

Global Pharma | 31/12/2024 | By Manvi |  161

Duality Biologics Announces License Exercise by BeiGene for B7H4 ADC

Duality Biologics announced that BeiGene Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074, securing global rights for the development, manufacturing, and commercialisation of the investigational therapy.

Global Pharma | 31/12/2024 | By Manvi |  219

Immedica Announces Acquisition of Marinus Pharmaceuticals

The acquisition complements and further strengthens Immedica’s global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, approved by the U.S. Food and Drug Administration (FDA) in March 2022.

Global Pharma | 31/12/2024 | By Aishwarya |  476

Vincerx Pharma Signs Binding Term Sheet for a Strategic Merger with Oqory

Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work.

Global Pharma | 31/12/2024 | By Aishwarya |  413

Precigen Completes Submission for BLA to USFDA for PRGN-2012

The submission is in the initial 60 day review period, during which time the FDA will decide whether to accept the BLA for further review and set the Prescription Drug User Fee Act (PDUFA) action date.

Global Pharma | 30/12/2024 | By Manvi |  422